Support our Commercialization With A Direct Investment

Investment Highlights:

• Capital equipment (the ultrasound otoscope), recurring revenue stream from the sale of consumables (the razorblades), patented, one-time-use disposable tips

• Multi-billion-dollar yearly revenue opportunity in the US alone, plus a global opportunity

• Blue ocean market space with huge growth potential, no other product on the market can identify bacterial middle ear infections, the information physicians need to determine if antibiotic therapy is appropriate.

• Outstanding early clinical results for detection of bacterial infected fluid in the middle ear

• Selected for the elite FDA Acceleration Program for technologies - validation that the OtoNexus otoscope provides a significant advantage over all currently available options

• More potential medical and industrial uses for the underlying ultrasound technology platform that are patent-protected

• Strong market pull from physicians, hospitals, and insurers

• Highly accomplished, world-class leadership team led by experts in medical device technology development, research and development, product commercialization, and scaling revenue growth

Intellectual Property Protection

OtoNexus has developed a patented technology for through-air ultrasound in medical and industrial applications. The first use miniaturized the technology to fit into the tip of an ear speculum. This new technology has also been designed to be manufactured inexpensively for single-use disposable applications. This patent provides a strong competitive edge, protecting our unique, innovative approach and securing our leadership position in the market. OtoNexus has received over 30 patents for this unique technology, creating a strong patent moat that strengthens the company’s competitive edge, protects its technology and revenue streams, and enhances market leadership.

Addressing a Critical Unmet Need

Middle ear infections are pervasive, particularly in young children, where accurate diagnosis is challenging. The OtoNexus ultrasound otoscope fills a critical gap by providing instant, non-invasive, and accurate detection of otitis media, addressing a significant unmet need in pediatric healthcare. Clinicians lack the tools for objective, accurate testing of middle ear infections. The technology for examining the ear remains subjective and has not changed in decades. The result is often the misdiagnosis of middle ear infections and the prescription of unnecessary antibiotics or specialist referrals. By providing clear, objective data, the OtoNexus ultrasound otoscope helps clinicians make accurate diagnoses, reducing the incidence of misdiagnoses and unnecessary treatments.

Verifiable Science and Proven Efficacy

Our device is built on well-established science and backed by clinical work and engineering testing to prove accuracy and reliability. This validation shows that our method works and our expectations for effectiveness and accuracy are justified. The capability to tell apart viral and bacterial infections is a significant step that will change treatment practices.

Clinical Partnerships and Adoption Strategy

We have established partnerships with leading healthcare institutions to conduct these clinical studies, ensuring that our device meets and exceeds the medical community's rigorous demands. Our strategic collaborations with top-tier healthcare organizations are instrumental in driving clinical adoption and facilitating the broader integration of our device into everyday clinical practice.

Scalable Manufacturing and Defined Production Approach

We have a clear, defined approach to product manufacturing and scaling. Our process is designed to meet growing demand while maintaining the highest standards of quality. The inclusion of disposable tips ensures a recurring revenue model and supports large-scale adoption.

The OtoNexus Ultrasound Otoscope: A Breakthrough in Middle Ear Infection Diagnosis

Resembling a traditional otoscope but with vastly superior capabilities, our device is compact enough to fit in a lab coat pocket. With the push of a button, clinicians receive definitive data on the presence and type of fluid in the ear, eliminating the need for invasive procedures. This data empowers both novice and expert clinicians to make swift, accurate diagnoses, significantly reducing the time to treatment.

Key Product Features and Advantages

• Instant Results: Provides immediate data, allowing for quick clinical decisions.

• User-Friendly: Simple design makes it accessible to a wide range of healthcare providers.

• Hygienic and Profitable: Disposable tips ensure hygiene and create a sustainable revenue stream.

• Accurate Differentiation: Distinguishes between viral and bacterial infections, leading to more effective treatments.

Industry Recognition:

OtoNexus was selected for the elite FDA Safer Technologies Program (STeP) in December of 2023. STeP is a pioneering initiative introduced by the FDA to identify and expedite the development and review of innovative medical devices that offer a significant advantage over all currently available options. Devices selected for the program provide radical improvements in patient care and patient safety.  STeP aims to provide patients with more timely access to these medical devices by providing STeP awardees expedited development and review, and interactive and timely communications, including sprint discussions, enhanced regulatory support, real-time feedback and direct advice, and other support.  The product must offer a significant advantage over currently available options to qualify. The evaluation process for the program requires comprehensive due diligence by the FDA to ensure the technology meets the strict, extensive criteria for the STeP program.

In addition, OtoNexus Medical Technologies is honored to have received awards and recognition from Keiretsu Capital (Most Valued Company), Keiretsu Forum MidAtlantic (Most Valued Company), Keiretsu Forum Northwest (Most Valued Company), Red Herring (Top 100 North America) Angel Capital Association (Most Investable Company), Puget Sound Business Journal (Washington’s 100 Best Workplaces), MedTech Outlook (Top 10 Infection Control Solution Providers), MedTech Strategist (Startups to Watch), Silicon Review (Innovative Companies to Watch) and Women Corporate Directors (Winner Launch Zone).

OtoNexus is also proud to be supported by Golden Seeds, an early-stage angel investment firm that champions and funds women-led startups.

Product Development Achievements:

• Patented Technology: Our unique proprietary application of through-air ultrasound technology, which has been miniaturized to fit into the tip of an ear speculum, has been patented, ensuring a competitive edge in the market.

• Clinical Validation: We have conducted highly successful clinical studies that demonstrate the exceptional accuracy and reliability of the ultrasound otoscope and validate its effectiveness.

• Strategic Partnerships: We have established collaborations with leading Children’s Hospitals, healthcare institutions, and organizations to further our mission and enhance our market reach.

Market Impact

Middle ear infections are the leading cause of antibiotic prescription and surgeries in children, resulting in significant healthcare costs and patient discomfort. The OtoNexus ultrasound otoscope solves these challenges by providing accurate, quick, and non-invasive detection of middle ear infections to improve patient care and reduce healthcare costs.

Future Developments

At OtoNexus, we are committed to continuous innovation and improvement. We are exploring additional applications of our unique through-air medical ultrasound technology to further enhance diagnostic capabilities and expand our product offerings. Our vision is to become a medtech innovator, providing healthcare professionals with the tools they need to deliver the best possible care to their patients.

A Personal Message from Caitlin Cameron, Chair and CEO

OtoNexus Medical Technologies is in the late stages of developing the world’s first medical device to instantly and accurately diagnose middle ear infections (Otitis Media).

Diagnostic uncertainty is removed by accurately identifying the type of infection and other states, and pediatricians and parents can be confident in determining antibiotic use. This can dramatically reduce unnecessary antibiotics and their long-term consequences.

Our inexpensive advanced ultrasound otoscope provides data in seconds and is easy to use by physicians or non-physician personnel worldwide. Definitive, objective data will lead to improved patient outcomes, better and faster treatment, reduced antibiotic usage, and significantly reduced healthcare costs.

We fill a huge gap and provide positive incentives to all parties involved: pediatricians, parents, insurance carriers, and medical societies; all understand the benefits of improved patient outcomes, reduced cost, and antimicrobial stewardship.

This revolutionary medical device will reinvent the ear exam.

I hope you will join us.

Caitlin Cameron, Chair and CEO,

OtoNexus Medical Technologies

Learn more about our investment opportunity

Our goal is to create a precision diagnostic tool that empowers clinicians with the confidence to make informed decisions, promotes efficient healthcare delivery, ensures patient safety, and aligns with public health guidelines on antibiotic stewardship.

OtoNexus is poised to set a new standard in medical diagnostics, offering an innovative solution that is essential in pediatric healthcare. Support our commercialization with a direct private equity investment. By investing in OtoNexus, you are supporting a medtech company dedicated to healthcare innovation and positively impacting global healthcare.

Contact us for more information about our investment opportunities and our go-to-market strategy.

Join Us in Revolutionizing Healthcare

OtoNexus Medical Technologies is dedicated to transforming middle ear infection diagnosis and treatment with a focus on accuracy, efficiency, and patient safety. By investing in OtoNexus, you support a company committed to enhancing pediatric healthcare, reducing unnecessary antibiotic use and surgical interventions, and improving outcomes for children with otitis media.